# Charles River Laboratories

Charles River Laboratories is a Corporate Investor based in Wilmington, United States.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Wilmington, United States
- **Region:** North America
- **Address:** Wilmington, MA, United States
- **Founded:** 1947
- **Assets under management:** Undisclosed
- **Website:** criver.com
- **LinkedIn:** https://www.linkedin.com/company/charles-river-laboratories
- **Wikidata:** Q5082076

## Regulatory record

- **Reports private funds:** No

## About

Charles River provides products and services to help expedite the discovery, early-stage development and safe manufacture of novel drugs and therapeutics.

## Sectors

- Healthcare Services
- Digital Health

## People

- James C. Foster — Chairman, President and CEO

## Questions

### How does Charles River Laboratories generate and deploy capital?

Charles River is a publicly traded corporation (NYSE: CRL), not a traditional investment vehicle — it generates cash from pharmaceutical clients paying for preclinical research services, then re-deploys earnings into laboratory facilities, animal colonies, and acquisitions. It does not manage third-party capital. Its growth has historically been acquisition-intensive, targeting niche research services and supply-chain assets that deepen its laboratory testing moat.

### What sectors does Charles River Laboratories focus its investment and acquisition strategy on?

Charles River targets the preclinical research supply chain: animal model breeding, microbial testing, biologics manufacturing support, cell and gene therapy services, and non-human primate supply. Its acquisitions aim to deepen vertical integration in drug-safety testing and expand into adjacent regulated laboratory services. It explicitly does not invest in clinical-stage assets or take drug-development risk.

### Where does the underlying value and business model come from?

The company's value derives from being the world's largest breeder of purpose-bred research rodents and a leading supplier of non-human primates — biological raw materials that are FDA-regulated and difficult to replicate. Combined with its safety-assessment laboratories, Charles River functions as essential outsourced infrastructure that every major pharmaceutical company relies on before a drug can enter human trials.

### How is Charles River Laboratories' ownership structured and is there meaningful family influence?

Charles River has been publicly traded since 2000. James C. Foster, son of the founder, has been CEO since 1992 and remains Chairman. While the Foster family does not hold a controlling equity stake, Jim Foster's 30-plus-year tenure as chief executive gives him unusual institutional influence over strategy, M&A, and long-term capital allocation for a widely held public company.

### What is the firm's known posture on acquisitions versus organic investment?

Charles River has historically pursued an aggressive acquisition strategy, completing over 60 deals during Foster's tenure. The M&A playbook targets bolt-on laboratory service providers and specialized research model suppliers that can be plugged into the company's global testing network. Its 2024 acquisition of Noveprim Group, a primate supplier, reflects the strategy of securing biological supply chains that regulators and pharmaceutical clients cannot easily replace.

## Related profiles

- [Channel Wealth](https://altss.com/profile/channel-wealth)
- [Charles Schwab](https://altss.com/profile/charles-schwab)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/charles-river-laboratories

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology